Table 2.

Random-Effects Meta-regression Models Estimating Trends in CD4 Count at Time of Presentation to HIV Care and Antiretroviral Therapy Initiation—Sub-Saharan Africa, 2002–2013

Model	Presentation to Care				Initiation of Antiretroviral Therapy
	Studies	β-Coefficient	95% CI	P Value	Studies	β-Coefficient	95% CI	P Value
Primary analyses	56	5.84	−10.7 to 22.4	.48	71	−1.13	−8.4 to 6.2	.76
Subanalyses
Opportunistic infections studies excluded	52	5.39	−11.3 to 22.1	.52	69	−0.55	−8.0 to 6.9	.88
PMTCT studies excluded	52	3.81	−14.1 to 21.7	.67	68	0.45	−4.8 to 5.7	.87
South Africa only	13	39.9	9.2 to 70.7	.016	10	2.36	−22.5 to 27.2	.83
Uganda only	…	…	…	…	11	4.20	−4.0 to 12.4	.28
Sensitivity analyses
Excluded studies >3 years	43	1.38	−18.3 to 21.1	.89	41	5.50	−1.6 to 12.6	.13
Disaggregated by yeara	56	6.52	−7.3 to 20.4	.35	71	3.91	−0.7 to 8.5	.10

Abbreviations: CI, confidence interval; PMTCT, prevention of mother-to-child transmission.

^a Model disaggregated by year, estimated using bootstrapping to account for clustering of data within studies.